Table 6 Summary of test results for patients with false negative results on the Well assay (n = 39)
From: Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
Subject ID | Well oral anti-HCV assay | Serum anti-HCV (Abbott assay) (S/Co) | OraQuick anti-HCV assaye | Serum anti-HCV (InTec assay) | HCV RNA (IU/mL) | Antiviral treatment |
|---|---|---|---|---|---|---|
30139 | – | 1.08 | NA | – | < 100 | no therapeutic indication |
30215 | – | 1.43 | NA | – | < 100 | no therapeutic indication |
30186 | – | 1.5 | NA | – | < 100 | no therapeutic indication |
30140 | – | 2.13 | NA | – | < 100 | no therapeutic indication |
20031 | – | 2.53 | – | – | < 100 | no therapeutic indication |
20122 | – | 2.9 | NA | – | < 100 | PEG-IFN and ribavirin, SVR |
20019 | – | 3.53 | – | – | < 100 | no therapeutic indication |
30168 | – | 4.12 | NA | – | < 100 | no therapeutic indication |
30228 | – | 4.47 | NA | – | < 100 | no therapeutic indication |
20038 | – | 4.59 | – | – | < 100 | no therapeutic indication |
30150 | – | 4.65 | NA | – | < 100 | no therapeutic indication |
20199 | – | 4.69 | NA | – | < 100 | no therapeutic indication |
30155 | – | 4.74 | NA | – | < 100 | no therapeutic indication |
30214 | – | 5.57 | NA | – | < 100 | no therapeutic indication |
30020 | – | 6.46 | – | – | < 100 | sofosbuvir/velpatasvir, SVR |
30195 | – | 7.03 | – | – | < 100 | no therapeutic indication |
30317 | – | 7.41 | NA | + | < 100 | sofosbuvir/daclatasvir, SVR |
30321 | – | 7.8 | NA | + | < 100 | no therapeutic indication |
20112 | – | 7.81 | NA | – | < 100 | PEG-IFN and ribavirin, SVR |
30108 | – | 8.2 | NA | – | < 100 | PEG-IFN and ribavirin, SVR |
30226 | – | 8.43 | NA | – | < 100 | no therapeutic indication |
30238 | – | 8.49 | NA | – | < 100 | PEG-IFN and ribavirin, SVR |
20010 | – | 11.07 | – | + | < 100 | sofosbuvir/velpatasvir, SVR |
30256 | – | 11.07 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
30245 | – | 11.97 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
20056 | – | 12.35 | NA | – | < 100 | no therapeutic indication |
30241 | – | 12.35 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
30162 | – | 12.69 | NA | + | < 100 | no therapeutic indication |
10287 | – | 12.98 | NA | + | < 100 | sofosbuvir and ribavirin, SVR |
10294 | – | 13.09 | NA | + | < 100 | sofosbuvir and ribavirin, SVR |
20095 | – | 13.1 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
30128 | – | 13.42 | NA | + | < 100 | sofosbuvir and ribavirin, SVR |
30251 | – | 13.51 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
20301 | – | 13.61 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
30249 | – | 13.81 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
20125 | – | 14.87 | NA | + | < 100 | elbasvir/grazoprevir, SVR |
30246 | – | 15.25 | NA | + | < 100 | PEG-IFN and ribavirin, SVR |
10025 | – | 15.72 | + | + | < 100 | no therapeutic indication |
20140 | – | 15.76 | NA | + | 6.38E+ 05 | treatment naive |